Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib combined with EGFR-TKI in EGFR-mutated non-small cell lung cancer
ChiCTR1900023837Phase 4Not yet recruiting
- Sponsor
- Shanxi Cancer Hospital
- Start
- Jun 2019
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Rivoceranib in non-small cell lung cancer (NSCLC), sponsored by Shanxi Cancer Hospital. Primary endpoint: Progression-free survival. Planned start Jun 2019; status: not yet recruiting.
02
Drugs
Rivoceranib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR1900023837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900023837.